Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Ive found that using a water bottle that tracks my intake can be extremely helpful for meeting my daily hydration goals
Ask us a question on WhatsApp
Emerging research on melanocortin-4 receptor (MC4R) agonists combined with GLP-1/GIP agonists has shown promise for enhanced weight loss and prevention of weight regain, potentially addressing the needs of patients who plateau on current monotherapy [53]
Armstrong MJ, Barton D, Gaunt P, et al
The infographic below summarises why this happens and the early cues we think are worth watching
What the clinical data has reported: Phase 2 trials of Retatrutide (Jastreboff et al., NEJM 2023, and follow-ups) reported: - Dose-dependent body weight reduction across 24- and 48-week dosing intervals - Reductions in liver fat content measured by MRI-proton density fat fraction (MRI-PDFF) in populations with metabolic dysfunction-associated steatotic liver disease (MASLD) - Glycaemic marker improvement (HbA1c, fasting glucose) in type 2 diabetes cohorts - Dose-related gastrointestinal adverse effects consistent with the GLP-1/GIP class nausea, vomiting, diarrhoea Important: these are clinical trial findings in regulated patient populations
US$ 26.10
,aspect=ignore)
US$ 22.47
US$ 27.86
US$ 23.25
